Blood
Blood research in orbit investigates how microgravity changes circulating blood volume, red blood cell mass and the balance between red-cell destruction and production. These measurements help explain the early “space anaemia” response and why it may persist during a long mission.
| 10–15% | Typical early reduction in red blood cell mass reported in spaceflight studies |
| +54% | Red-cell destruction measured during a six-month ISS study |
| ~167 days | Approximate mission duration in the MARROW astronaut study |
How it was studied
Researchers collected blood before, during and after flight and assessed haematological measures, including red-cell mass, haemoglobin-related indicators, reticulocytes and markers associated with red-cell breakdown. The MARROW investigation combined blood sampling with other measurements of bone-marrow and blood-cell function. Comparing these results across mission phases helped distinguish the initial fluid shift from continuing changes in red-cell turnover.
Results and analysis
Earlier flight studies described a rapid decrease in red-cell mass, commonly around 10–15%, during the first days of weightlessness. NASA’s summary of the MARROW findings reports that the astronauts studied destroyed about three million red blood cells per second in space, compared with about two million per second on Earth. The increased destruction continued beyond the initial fluid redistribution, so the phenomenon cannot be explained solely as a short-lived adjustment.
Conclusions
Spaceflight changes red-cell regulation, with an early reduction in red-cell mass and increased destruction that can continue throughout a long mission. Blood monitoring is therefore important not only at launch and landing but also during flight. The exact clinical consequences and the best nutritional or medical countermeasures still require further study.
Bone
In microgravity, weight-bearing bones no longer experience the mechanical loading they receive on Earth. Bone formation and resorption become unbalanced, reducing density and, in some cases, the structural strength of the hip and spine.
| 1–1.5% | Average monthly density loss in weight-bearing bones during long missions |
| ~6 months | Typical ISS mission duration represented in the principal evidence |
| ~1 year | Approximate time reported for lumbar density recovery in a small follow-up group |
How it was studied
NASA and partner teams compare pre-flight and post-flight bone scans, principally using dual-energy X-ray absorptiometry (DXA), with quantitative CT used in some studies to examine bone structure and strength. Blood and urine markers of bone turnover, including resorption markers, provide additional information about how quickly bone tissue is being broken down. Exercise countermeasures such as the Advanced Resistive Exercise Device (ARED), and in some studies bisphosphonate medication, are assessed against these outcomes.
Results and analysis
The supplied report and NASA’s risk summary place average loss in weight-bearing bone at roughly 1–1.5% per month during four-to-six-month missions. The rate varies by skeletal region and by astronaut. ARED reduces losses but does not eliminate them in every study. The supplied report also describes better hip protection when resistance exercise was combined with alendronate, although the treatment group was small.
The regional values in the first chart are not interchangeable: they come from different measurement methods and cohorts. NASA’s broad summary remains approximately 1–1.5% per month in weight-bearing bones.
Conclusions
Bone loss is a cumulative risk of long-duration missions. Exercise is essential and reduces deconditioning, but it does not fully prevent skeletal changes. Monitoring density and turnover, maintaining adequate nutrition and evaluating combined countermeasures are central to protecting astronauts during exploration missions.
Radiation
Outside Earth’s protective atmosphere and much of its magnetic shielding, astronauts are exposed to galactic cosmic rays, trapped particles and occasional solar particle events. Radiation studies quantify exposure so that mission planners can manage cumulative risk.
| 0.2–0.5 mSv | Per day: typical ISS effective-dose range cited in the supplied report |
| ~40–90 mSv | Estimated total for a typical six-month ISS mission |
| 600 mSv | NASA career effective-dose limit in the cited NASA-STD-3001 requirement |
How it was studied
Radiation is monitored using passive dosimeters and, more recently, personal active dosimeters that record exposure over time. Area monitors aboard the ISS measure the radiation environment at different locations. The Space Radiation Analysis Group uses these measurements to estimate crew exposure and support operational decisions. Readings depend on orbital altitude, solar activity, shielding, location inside the station and the type of detector.
Results and analysis
The supplied report gives a typical ISS effective-dose rate of 0.2–0.5 mSv per day and an estimated 40–90 mSv over six months. NASA’s radiation material also describes approximately 0.5 mSv per day as a representative ISS value. The career limit is 600 mSv under the cited current NASA standard.
The charts below also include Mars cruise and Mars surface values taken from RAD/Curiosity measurements. These are estimates for missions beyond low Earth orbit, not outcomes observed in astronauts, and exposure there is highly variable.
Conclusions
Radiation is a cumulative mission constraint rather than a symptom that can be assessed from a single clinical test. Continuous or repeated dosimetry, shielding strategies and solar-event monitoring are essential. A six-month ISS dose is well below the 600 mSv career limit, but deep-space missions may involve a more challenging radiation environment.
Optical
Long-duration spaceflight can alter the structure of the eye and the visual system. NASA groups several of these findings under Spaceflight Associated Neuro-ocular Syndrome (SANS), which is associated with fluid shifts toward the head but is not yet fully understood.
| ~70% | ISS astronauts reported by NASA to experience some swelling at the back of the eye |
| +0.75 D | Hyperopic refractive shift used as one clinical indicator in SANS assessment |
| OCT | Imaging method used to examine retinal and optic-nerve structures |
How it was studied
Eye health is assessed before, during and after flight using visual-acuity and refraction tests, fundus photographs, optical coherence tomography (OCT), ocular ultrasound and tonometry. OCT allows researchers to measure retinal layers and optic-disc changes, while ultrasound can help assess the shape of the globe and surrounding structures. These measurements are compared with the astronaut’s pre-flight baseline and followed after return to Earth.
Results and analysis
NASA describes optic-disc swelling, chorioretinal folds, flattening of the back of the eye and hyperopic shifts among the observed findings. Its current public risk material estimates that around 70% of ISS astronauts experience some swelling at the back of the eye. The frequency and severity vary between individuals, and the mechanisms and long-term consequences remain active research questions. NASA also notes that the clinical significance of intraocular-pressure changes is still uncertain.
Conclusions
Ocular monitoring is a key part of long-duration astronaut health surveillance. The combination of imaging and functional tests is more informative than relying on visual acuity alone. SANS is common enough to warrant routine assessment, but individual outcomes differ and the underlying mechanisms are not fully resolved.
Sleep
Sleep research examines how mission schedules, workload, light exposure and the unusual 90-minute day-night cycle in low Earth orbit affect sleep duration and circadian timing. Sleep is relevant to alertness, decision-making and operational performance.
| ~6.1 h | Average sleep per night in the ISS cohort in Barger et al. (2014) |
| 8.5 h | Sleep opportunity scheduled by NASA |
| 24% | ISS nights with at least seven hours of sleep in the Barger dataset |
How it was studied
Researchers used wrist-worn actigraphy, sleep logs and questionnaires to estimate sleep duration and timing before, during and after missions. In the Barger et al. observational study, sleep was assessed across 80 Shuttle missions and 13 ISS missions, with thousands of nights of ground and in-flight data. These methods make it possible to compare sleep across mission phases and identify the effects of schedule changes and operational demands.
Results and analysis
The supplied report and NASA’s sleep technical brief describe average in-flight sleep of roughly six hours per night. In the ISS group of Barger et al., the mean was 6.09 hours, compared with 6.41 hours in the pre-flight reference interval and 6.95 hours in the first week after return. NASA notes that astronauts commonly experience circadian misalignment and that noise, temperature, discomfort and mission conditions can disrupt sleep.
Conclusions
Sleep restriction is a well-documented operational concern in spaceflight, although it is not inevitable: schedules and sleep environments can make a meaningful difference. Protecting adequate sleep opportunity, managing light and shift changes, and monitoring fatigue are important countermeasures for long missions.
Selected NASA references
The following NASA material was used to check the interpretation and numerical context of the studies above.
- NASA — Scientists Find Increased Red Blood Cell Destruction During Spaceflight
- NASA — Risk of Spaceflight-Induced Bone Changes
- NASA — Risk of Spaceflight Associated Neuro-ocular Syndrome (SANS)
- NASA-STD-3001 — Human Performance and career radiation exposure limit
- NASA OCHMO-TB-041 — Sleep Accommodations
- Barger et al. — Sleep deficiency before, during and after spaceflight
- NASA Space Radiation Analysis Group — Crew Active Dosimeters
Chart sources. Alfrey et al. and NASA NTRS (plasma volume and red-cell mass); Trudel et al., Nature Medicine, 2022; UCSF/Baylor and Keyak et al. (hip strength); Sibonga et al., Bone, 2019; meta-analysis PMC7200725; Mader et al., Ophthalmology, 2011; NASA NTRS SANS 2023; Costantino et al.; Zeitlin et al. and RAD/Hassler; Barger et al., Lancet Neurology, 2014; Mars-500, PLOS ONE, 2014.